The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The PAM gene (UniProt: A0A8C2TBA7) in Japanese quail (Coturnix japonica) encodes peptidylglycine alpha-amidating monooxygenase, a highly conserved bifunctional enzyme responsible for C-terminal amidation of bioactive peptides. The protein domains listed in UniProt—including Cu2_ascorb_mOase domains and a 6-blade β-propeller structure—match the well-characterized structural features of PAM across species, confirming correct gene identification (prigge2000newinsightsinto pages 1-3, eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2).
PAM is the sole enzyme known to catalyze C-terminal α-amidation of peptides, a post-translational modification essential for the biological activity of over 70 bioactive peptides (merkler2022peptidylglycineα‐amidatingmonooxygenase pages 1-2, ilina2025enhancingstabilityand pages 1-2). The enzyme operates through a two-step sequential mechanism carried out by two distinct catalytic domains within a single polypeptide (prigge2000newinsightsinto pages 1-3, eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2).
Step 1: Peptidylglycine α-Hydroxylating Monooxygenase (PHM)
The N-terminal PHM domain catalyzes the stereospecific hydroxylation of the α-carbon of the C-terminal glycine residue. This rate-limiting step requires three essential cofactors: (1) copper ions (two copper atoms per PHM domain), (2) molecular oxygen, and (3) reduced ascorbate as an electron donor. One mole of ascorbate is consumed per mole of amidated product formed (prigge2000newinsightsinto pages 1-3, murthy1986purificationandcharacterization pages 1-2).
Step 2: Peptidyl-α-Hydroxyglycine α-Amidating Lyase (PAL)
The PAL domain cleaves the peptidyl-α-hydroxyglycine intermediate produced by PHM to generate the α-amidated peptide product and glyoxylate. At physiological pH, this second step proceeds efficiently to completion (prigge2000newinsightsinto pages 1-3, eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2, husten1993useofendoproteases pages 1-2).
PAM exhibits remarkably broad substrate specificity, capable of producing α-amides of all 20 amino acids from their glycine-extended precursors (prigge2000newinsightsinto pages 3-4, eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2). In vitro studies have demonstrated that PAM can also process non-peptide substrates including fatty acyl glycines, suggesting additional potential physiological roles (prigge2000newinsightsinto pages 3-4). The enzyme's broad specificity allows it to serve as the universal amidating enzyme for diverse peptide hormones and neuropeptides.
PAM is synthesized with an N-terminal signal sequence that directs co-translational insertion into the endoplasmic reticulum (ER). The protein includes a short proregion that facilitates efficient ER exit and trafficking through the early secretory pathway (milgram1992expressionofindividual pages 1-2). PAM then transits through the Golgi complex, with particularly strong localization to the trans-Golgi network (TGN), where secretory granules originate and peptide processing machinery converges (milgram1992expressionofindividual pages 1-2, alam2001signalingmediatedby pages 1-2).
PAM is packaged into regulated secretory granules and neurosecretory vesicles, where it exists in both membrane-associated and soluble forms. In atrial cardiomyocytes, PAM represents a major membrane protein of secretory granules (back2020peptidylglycineαamidatingmonooxygenase pages 1-3). Subcellular fractionation studies of hypothalamus and hippocampus demonstrate that both PHM and PAL enzymatic activities localize predominantly to neurosecretory vesicle-enriched fractions (oyarce1993neurosecretoryvesiclescontain pages 1-2). Within these granules, approximately 30-40% of PAM activity is found in the soluble fraction, while the remainder remains membrane-associated even after removal of peripheral proteins (oyarce1993neurosecretoryvesiclescontain pages 1-2).
During regulated secretion, membrane-bound PAM can transiently visit the cell surface before either being internalized or remaining on the plasma membrane. Soluble PAM forms generated through endoproteolytic processing can be secreted into the extracellular space in active form (milgram1992expressionofindividual pages 1-2, oyarce1993neurosecretoryvesiclescontain pages 1-2, merkler2022peptidylglycineα‐amidatingmonooxygenase pages 1-2).
Recent evidence demonstrates PAM localization to cilia in diverse eukaryotes, where it contributes to peptidergic signaling and ciliary ectosome-mediated secretion (luxmi2024ciliaprovidea pages 1-2).
The cytoplasmic domain of membrane PAM contains routing signals essential for proper subcellular localization. Recent work has revealed that PAM undergoes COPI vesicle-mediated recycling from the cis-Golgi back to the ER, a process critical for secretory granule biogenesis (back2020peptidylglycineαamidatingmonooxygenase pages 1-3).
PAM-dependent α-amidation is required for the full biological activity of numerous peptide hormones and neuropeptides. Major substrates include:
(prigge2000newinsightsinto pages 1-3, eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2, ilina2025enhancingstabilityand pages 1-2, luxmi2024ciliaprovidea pages 1-2)
The α-amide modification typically enhances receptor affinity by several orders of magnitude, protects peptides from carboxypeptidase degradation, and is often absolutely required for biological activity (prigge2000newinsightsinto pages 3-4, luxmi2024ciliaprovidea pages 1-2, ilina2025enhancingstabilityand pages 1-2).
PAM functions as a late-stage enzyme in the regulated secretory pathway, operating downstream of the subtilisin-like prohormone convertases (PC1, PC2) and carboxypeptidase E/H. After initial endoproteolytic cleavage of prohormone precursors and trimming of basic residues, PAM converts glycine-extended intermediates into their mature α-amidated forms within secretory granules (eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2, merkler2022peptidylglycineα‐amidatingmonooxygenase pages 1-2, alam2001signalingmediatedby pages 1-2).
Beyond its catalytic function, PAM plays a structural role in secretory granule formation and maturation. Studies using cardiomyocyte-specific PAM knockout mice revealed an approximately 13-fold reduction in secretory granule number, demonstrating that PAM is required for granule biogenesis (back2020peptidylglycineαamidatingmonooxygenase pages 1-3). Strikingly, this requirement for granule formation does not depend on PAM's monooxygenase catalytic activity, indicating a structural or scaffolding function (back2020peptidylglycineαamidatingmonooxygenase pages 1-3).
The cytoplasmic domain of membrane-bound PAM functions as a signaling hub, interacting with multiple cytosolic proteins:
These interactions link luminal peptide processing events to cytoplasmic processes including actin cytoskeleton organization and secretory granule trafficking. Overexpression of PAM in corticotrope cells reorganizes the actin cytoskeleton and affects the distribution of ACTH-containing granules, effects that depend on the ability of PAM to interact with P-CIP2 (alam2001signalingmediatedby pages 1-2).
PAM activity exhibits striking sensitivity to hypoxia in human, mouse, and insect cells. Peptide amidation decreases progressively from mild (7% O₂) to severe (1% O₂) hypoxia, with sensitivity comparable to the hypoxia-inducible factor (HIF) system. This suggests PAM may function as a monooxygenase-based oxygen sensor that modulates peptidergic signaling pathways in response to changes in oxygen availability (simpson2015strikingoxygensensitivity pages 1-2).
A 2025 study demonstrated that PEGylation markedly extends PAM's half-life in circulation. Single subcutaneous, intramuscular, or intraperitoneal administration of PEGylated PAM resulted in sustained elevation of circulating amidating activity for up to seven days, with peak activity at 12-24 hours post-administration and no observable adverse effects. This advance positions PAM as a potential therapeutic agent for conditions involving deficient amidated peptide production (ilina2025enhancingstabilityand pages 1-2).
Development of a sensitive immunoassay for quantifying full-length PAM in human plasma (detection limit 189 pg/mL) has enabled population-based studies. Application to 4,850 individuals in a Swedish cohort supports PAM's utility as a biomarker for various pathophysiological conditions (ilina2025enhancingstabilityand pages 1-2).
Germline loss-of-function PAM variants were found to be enriched in subjects with pituitary hypersecretion. Functional characterization revealed that different variants impact PAM through distinct mechanisms affecting expression, catalytic activity, trafficking, and RNA splicing. UK Biobank data confirmed significant associations between rare PAM variants and diagnoses related to pituitary gland hyperfunction (luxmi2024ciliaprovidea pages 1-2).
A 2023 study identified "capped peptides"—fragments of secreted proteins bearing both N-terminal pyroglutamylation and C-terminal amidation—as a new class of circulating signaling molecules. Examples include CAP-TAC1, a nanomolar tachykinin receptor agonist, and CAP-GDF15, which reduces food intake and body weight in mice (luxmi2024ciliaprovidea pages 1-2).
Research in 2024 linked PAM expression in hypothalamic POMC neurons to metabolic homeostasis. Deletion of Fam172a in POMC neurons increases histone lactylation, upregulates PAM expression, and affects α-melanocyte-stimulating hormone (α-MSH) synthesis, ultimately protecting against diet-induced obesity (luxmi2024ciliaprovidea pages 1-2).
Expression of mammalian PAM in Nicotiana benthamiana plants enabled efficient production of bioactive amidated antimicrobial peptides. These plant-produced amidated peptides demonstrated robust activity against drug-resistant ESKAPE pathogens and prevented biofilm formation, illustrating PAM's utility in biomanufacturing applications (luxmi2024ciliaprovidea pages 1-2).
| Section | Topic | Key details | Evidence / examples | Citations |
|---|---|---|---|---|
| Primary enzymatic function | Overall reaction | PAM is the only known enzyme that catalyzes C-terminal α-amidation of glycine-extended peptide substrates, a modification required for full activity of many peptide hormones and neuropeptides. In higher animals, PAM is a single bifunctional polypeptide containing two catalytic activities. | Converts peptidyl-Gly precursors into amidated peptide + glyoxylate via a two-step pathway. | (prigge2000newinsightsinto pages 1-3, eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2, merkler2022peptidylglycineα‐amidatingmonooxygenase pages 1-2, ilina2025enhancingstabilityand pages 1-2) |
| Primary enzymatic function | PHM domain reaction | The N-terminal peptidylglycine α-hydroxylating monooxygenase (PHM) domain performs the first, rate-limiting step: stereospecific hydroxylation of the α-carbon of the terminal glycine. This step requires copper, molecular oxygen, and reduced ascorbate. | PHM contains two copper atoms; one mole of ascorbate is consumed per mole of amidated product in assay systems. | (prigge2000newinsightsinto pages 1-3, eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2, murthy1986purificationandcharacterization pages 1-2) |
| Primary enzymatic function | PAL domain reaction | The C-terminal peptidyl-α-hydroxyglycine α-amidating lyase (PAL) domain cleaves the peptidyl-α-hydroxyglycine intermediate to generate the α-amidated peptide product and glyoxylate. | PAL is the second catalytic activity in the bifunctional enzyme; the intermediate can be relatively stable under acidic granule conditions. | (prigge2000newinsightsinto pages 1-3, eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2, husten1993useofendoproteases pages 1-2) |
| Primary enzymatic function | Substrate specificity | PAM has broad substrate specificity, producing amides of all 20 amino acids; activity is primarily directed to peptides bearing a C-terminal glycine extension, though non-peptide and fatty acyl glycine substrates have also been described in biochemical studies. | Substrates include classical neuropeptide precursors and, in vitro, fatty acyl glycines such as oleamide precursors. | (prigge2000newinsightsinto pages 3-4, eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2, merkler2022peptidylglycineα‐amidatingmonooxygenase pages 1-2) |
| Subcellular localization | ER and early secretory pathway | PAM is synthesized with an N-terminal signal peptide and enters the endoplasmic reticulum; its proregion facilitates efficient ER exit and early secretory pathway trafficking. | The proregion promotes secretion/trafficking of soluble proteins and PAM normally exits the ER relatively slowly without it. | (prigge2000newinsightsinto pages 1-3, milgram1992expressionofindividual pages 1-2) |
| Subcellular localization | Golgi / TGN | PAM localizes strongly to the perinuclear Golgi region and trans-Golgi network, where peptide processing machinery converges and secretory granules originate. | Immunocytochemistry in AtT-20 cells showed PAM in the perinuclear region near the Golgi; overexpression can trap cargo in the TGN region. | (milgram1992expressionofindividual pages 1-2, alam2001signalingmediatedby pages 1-2) |
| Subcellular localization | Secretory granules / neurosecretory vesicles | PAM is packaged into regulated secretory granules and neurosecretory vesicles as both membrane-associated and soluble mono-/bifunctional forms. In atrial myocytes, PAM is a major granule membrane protein. | Subcellular fractionation of brain tissue localized PHM and PAL activities to vesicle-enriched fractions; atrial PAM loss causes a marked granule deficit. | (oyarce1993neurosecretoryvesiclescontain pages 1-2, back2020peptidylglycineαamidatingmonooxygenase pages 1-3, husten1991themembraneboundbifunctional pages 1-2) |
| Subcellular localization | Plasma membrane / extracellular release | Membrane PAM can visit the cell surface during secretion, and soluble PAM forms can be released extracellularly after endoproteolytic processing or secretion from granules. | Soluble PAM proteins are secreted in active form; membrane-associated forms may remain on the surface or be internalized. | (milgram1992expressionofindividual pages 1-2, oyarce1993neurosecretoryvesiclescontain pages 1-2, merkler2022peptidylglycineα‐amidatingmonooxygenase pages 1-2) |
| Subcellular localization | Cilia | PAM and amidated peptide products have also been localized to cilia, where they contribute to peptidergic signaling and ectosome-mediated secretion in diverse eukaryotes. | Ciliary localization documented in a 2024 review synthesizing data from algae and metazoans. | (luxmi2024ciliaprovidea pages 1-2) |
| Biological substrates | Major amidated peptide classes | PAM-dependent amidation is required for many bioactive peptides, including vasopressin, oxytocin, neuropeptide Y, substance P, cholecystokinin, gastrin, calcitonin, adrenomedullin, CGRP, amylin, PACAP, and VIP. | Reviews note that more than half of peptide hormones require amidation; recent therapeutic discussion lists ADM, CGRP, amylin, NPY, PACAP, VIP and others. | (prigge2000newinsightsinto pages 1-3, eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2, ilina2025enhancingstabilityand pages 1-2, luxmi2024ciliaprovidea pages 1-2) |
| Biological substrates | Functional consequence of amidation | C-terminal amidation typically enhances receptor affinity, protects against carboxypeptidase attack/proteolysis, and is often essential for full biological activity. | Loss of the amide commonly reduces peptide signaling potency; cilia review notes receptor affinity can improve by orders of magnitude. | (prigge2000newinsightsinto pages 3-4, luxmi2024ciliaprovidea pages 1-2, ilina2025enhancingstabilityand pages 1-2) |
| Biochemical pathways | Position in peptide maturation pathway | PAM acts late in the regulated secretory pathway after precursor cleavage by subtilisin-like endoproteases and trimming by carboxypeptidase E/H, converting glycine-extended intermediates into mature amidated signals. | PAM is discussed alongside PC1/PC2 and carboxypeptidase E in secretory granule peptide maturation. | (eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2, merkler2022peptidylglycineα‐amidatingmonooxygenase pages 1-2, alam2001signalingmediatedby pages 1-2) |
| Biochemical pathways | Trafficking and granule biogenesis | Beyond catalysis, PAM participates in secretory pathway organization, including granule formation/maturation and COPI-dependent recycling between Golgi and ER. | In atrial myocytes, PAM loss causes ~13-fold fewer granules and altered proANP handling; COPI-mediated recycling of PAM from cis-Golgi to ER was implicated. | (back2020peptidylglycineαamidatingmonooxygenase pages 1-3) |
| Signaling functions | Cytosolic domain signaling | The cytosolic domain of membrane PAM binds signaling/trafficking regulators including P-CIP2 and Kalirin, linking luminal peptide-processing events to cytoskeletal organization and granule trafficking. | Mutating a PAM cytosolic interaction site restored regulated secretion and prevented abnormal ACTH redistribution in corticotrope cells. | (alam2001signalingmediatedby pages 1-2) |
| Signaling functions | Oxygen sensing | PAM catalytic output is strikingly oxygen-sensitive in cells, suggesting a monooxygenase-based oxygen-sensing mechanism affecting peptidergic pathways under hypoxia. | Amidation of chromogranin A- and POMC-derived products falls progressively from mild to severe hypoxia. | (simpson2015strikingoxygensensitivity pages 1-2) |
| Recent developments (2023-2025) | Human genetics and endocrine disease | Rare germline loss-of-function PAM variants were enriched in subjects with pituitary hypersecretion; functional testing showed effects on expression, trafficking, splicing, and amidation activity. | Study combined family-based discovery, in vitro functional analysis, and UK Biobank support. | (luxmi2024ciliaprovidea pages 1-2) |
| Recent developments (2023-2025) | New amidated signaling peptide space | A 2023 study identified circulating “capped peptides” bearing N-terminal pyroglutamylation and C-terminal amidation, expanding the landscape of potential PAM-dependent signaling molecules. | CAP-TAC1 acted as a nanomolar tachykinin receptor agonist; CAP-GDF15 reduced food intake/body weight in mice. | (luxmi2024ciliaprovidea pages 1-2) |
| Recent developments (2023-2025) | Metabolic regulation | In 2024, hypothalamic POMC-neuron work linked increased PAM expression to altered α-MSH synthesis in a lactate/histone-lactylation pathway affecting energy balance and obesity phenotypes. | PAM upregulation was associated with changes in amidated α-MSH production downstream of Fam172a/lactylation changes. | (luxmi2024ciliaprovidea pages 1-2) |
| Recent developments (2023-2025) | Biomarker / assay development | A 2023 immunoassay enabled quantification of full-length PAM in human plasma with application to a population-based cohort of 4,850 individuals, supporting biomarker development. | Reported detection limit 189 pg/mL, quantification limit 250 pg/mL, and good assay precision/stability. | (ilina2025enhancingstabilityand pages 1-2) |
| Recent developments (2023-2025) | Therapeutic engineering | A 2025 study showed PEGylation markedly prolonged circulating PAM activity in rats, with increased amidating activity persisting up to 7 days after single-dose administration. | Peak activity at 12–24 h after s.c./i.m./i.p. dosing; no obvious adverse effects reported. | (ilina2025enhancingstabilityand pages 1-2) |
| Recent developments (2023-2025) | Biotechnology application | Mammalian PAM expressed in plants enabled production of bioactive amidated antimicrobial peptides active against drug-resistant ESKAPE pathogens, illustrating real-world biomanufacturing use. | Amidated AMPs produced in Nicotiana benthamiana showed antibacterial activity and anti-biofilm effects. | (luxmi2024ciliaprovidea pages 1-2) |
Table: This table summarizes the core enzymatic role, trafficking, substrates, signaling functions, and recent translational developments for peptidylglycine α-amidating monooxygenase. It is useful as a compact evidence-backed reference for functional annotation of the Japanese quail PAM ortholog.
PAM in Coturnix japonica is a highly conserved bifunctional enzyme essential for the biosynthesis of α-amidated bioactive peptides. The enzyme catalyzes a two-step copper-, oxygen-, and ascorbate-dependent reaction that converts glycine-extended peptide precursors into their mature amidated forms. PAM localizes throughout the secretory pathway from the ER through secretory granules and can be released extracellularly. Beyond its catalytic function, PAM plays structural roles in granule biogenesis and signaling roles through its cytosolic domain. Recent advances highlight PAM's potential as a therapeutic agent, disease biomarker, and biotechnology tool, while genetic studies continue to reveal its importance in human endocrine physiology and metabolic regulation.
References
(prigge2000newinsightsinto pages 1-3): S. T. Prigge, R. E. Mains, B. A. Eipper, and L. M. Amzel *. New insights into copper monooxygenases and peptide amidation: structure, mechanism and function. Aug 2000. URL: https://doi.org/10.1007/pl00000763, doi:10.1007/pl00000763. This article has 568 citations and is from a domain leading peer-reviewed journal.
(eipper1993peptidylglycineα‐amidatingmonooxygenase pages 1-2): Betty A. Eipper, Sharon L. Milgram, E. Jean Husten, Hye‐Young Yun, and Richard E. Mains. Peptidylglycine α‐amidating monooxygenase: a multifunctional protein with catalytic, processing, and routing domains. Protein Science, 2:489-497, Apr 1993. URL: https://doi.org/10.1002/pro.5560020401, doi:10.1002/pro.5560020401. This article has 363 citations and is from a peer-reviewed journal.
(merkler2022peptidylglycineα‐amidatingmonooxygenase pages 1-2): David J. Merkler, Aidan J. Hawley, Betty A. Eipper, and Richard E. Mains. Peptidylglycine α‐amidating monooxygenase as a therapeutic target or biomarker for human diseases. British Journal of Pharmacology, 179:3306-3324, Feb 2022. URL: https://doi.org/10.1111/bph.15815, doi:10.1111/bph.15815. This article has 28 citations and is from a highest quality peer-reviewed journal.
(ilina2025enhancingstabilityand pages 1-2): Yulia Ilina, Paul Kaufmann, Michaela Press, Theo Ikenna Uba, and Andreas Bergmann. Enhancing stability and bioavailability of peptidylglycine alpha-amidating monooxygenase in circulation for clinical use. Feb 2025. URL: https://doi.org/10.3390/biom15020224, doi:10.3390/biom15020224. This article has 4 citations.
(murthy1986purificationandcharacterization pages 1-2): A S Murthy, R E Mains, and B A Eipper. Purification and characterization of peptidylglycine alpha-amidating monooxygenase from bovine neurointermediate pituitary. Journal of Biological Chemistry, 261:1815-1822, Feb 1986. URL: https://doi.org/10.1016/s0021-9258(17)36013-1, doi:10.1016/s0021-9258(17)36013-1. This article has 197 citations and is from a domain leading peer-reviewed journal.
(husten1993useofendoproteases pages 1-2): E.J. Husten, F.A. Tausk, H.T. Keutmann, and B.A. Eipper. Use of endoproteases to identify catalytic domains, linker regions, and functional interactions in soluble peptidylglycine alpha-amidating monooxygenase. The Journal of biological chemistry, 268 13:9709-17, May 1993. URL: https://doi.org/10.1016/s0021-9258(18)98406-1, doi:10.1016/s0021-9258(18)98406-1. This article has 54 citations.
(prigge2000newinsightsinto pages 3-4): S. T. Prigge, R. E. Mains, B. A. Eipper, and L. M. Amzel *. New insights into copper monooxygenases and peptide amidation: structure, mechanism and function. Aug 2000. URL: https://doi.org/10.1007/pl00000763, doi:10.1007/pl00000763. This article has 568 citations and is from a domain leading peer-reviewed journal.
(milgram1992expressionofindividual pages 1-2): Sharon L. Milgram, Richard C. Johnson, and R. Mains. Expression of individual forms of peptidylglycine alpha-amidating monooxygenase in att-20 cells: endoproteolytic processing and routing to secretory granules. The Journal of cell biology, 117:717-728, May 1992. URL: https://doi.org/10.1083/jcb.117.4.717, doi:10.1083/jcb.117.4.717. This article has 127 citations.
(alam2001signalingmediatedby pages 1-2): M. Rashidul Alam, Tami C. Steveson, Richard C. Johnson, Nils Bäck, Benjamin Abraham, Richard E. Mains, and Betty A. Eipper. Signaling mediated by the cytosolic domain of peptidylglycine α-amidating monooxygenase. Molecular Biology of the Cell, 12:629-644, Mar 2001. URL: https://doi.org/10.1091/mbc.12.3.629, doi:10.1091/mbc.12.3.629. This article has 40 citations and is from a domain leading peer-reviewed journal.
(back2020peptidylglycineαamidatingmonooxygenase pages 1-3): Nils Bäck, Raj Luxmi, Kathryn G. Powers, Richard E. Mains, and Betty A. Eipper. Peptidylglycine α-amidating monooxygenase is required for atrial secretory granule formation. Proceedings of the National Academy of Sciences, 117:17820-17831, Jul 2020. URL: https://doi.org/10.1073/pnas.2004410117, doi:10.1073/pnas.2004410117. This article has 35 citations and is from a highest quality peer-reviewed journal.
(oyarce1993neurosecretoryvesiclescontain pages 1-2): Ana Maria Oyarce and Betty A. Eipper. Neurosecretory vesicles contain soluble and membrane‐associated monofunctional and bifunctional peptidylglycine α‐amidating monooxygenase proteins. Journal of Neurochemistry, 60:1105-1114, Mar 1993. URL: https://doi.org/10.1111/j.1471-4159.1993.tb03261.x, doi:10.1111/j.1471-4159.1993.tb03261.x. This article has 40 citations and is from a domain leading peer-reviewed journal.
(luxmi2024ciliaprovidea pages 1-2): Raj Luxmi and Stephen M. King. Cilia provide a platform for the generation, regulated secretion, and reception of peptidergic signals. Cells, 13:303, Feb 2024. URL: https://doi.org/10.3390/cells13040303, doi:10.3390/cells13040303. This article has 4 citations.
(simpson2015strikingoxygensensitivity pages 1-2): Peter D. Simpson, Betty A. Eipper, Maximiliano J. Katz, Lautaro Gandara, Pablo Wappner, Roman Fischer, Emma J. Hodson, Peter J. Ratcliffe, and Norma Masson. Striking oxygen sensitivity of the peptidylglycine α-amidating monooxygenase (pam) in neuroendocrine cells. Journal of Biological Chemistry, 290:24891-24901, Oct 2015. URL: https://doi.org/10.1074/jbc.m115.667246, doi:10.1074/jbc.m115.667246. This article has 32 citations and is from a domain leading peer-reviewed journal.
(husten1991themembraneboundbifunctional pages 1-2): E.J. Husten and B.A. Eipper. The membrane-bound bifunctional peptidylglycine alpha-amidating monooxygenase protein. exploration of its domain structure through limited proteolysis. The Journal of biological chemistry, 266 26:17004-10, Sep 1991. URL: https://doi.org/10.1016/s0021-9258(19)47332-8, doi:10.1016/s0021-9258(19)47332-8. This article has 76 citations.